Vidac Pharma Announces First Patient Dosed in Phase‑2b Study of VDA‑1102 for High‑Risk Actinic Keratosis
Vidac Pharma’s first patient dose in Phase‑2b VDA‑1102 for high‑risk actinic keratosis marks a pivotal milestone, advancing a promising dermatologic therapy.
2 minutes to read